Acasti Pharma

Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Laval, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.

Acasti Pharma stock plunged after the company reported negative trial results. The company's road ahead is filled with risks.

Acasti Pharma Is a Risky Play After Releasing Disappointing Data

Acasti Pharma stock collapsed following an unsuccessful Phase 3 clinical trial. But even this major setback isn't the only headwind impacting shares.

The Reward Is Not Worth the Risk for Acasti Pharma Stock

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2020 Results - Earnings Call Transcript

Acasti Pharma stock jumped higher last year on the potential of Acasti’s krill-oil extract CaPre. But a closer examination of its Phase 3 results suggests not all is well with the company.

Acasti Pharma Stock Is Bleeding Both Value and Credibility

Acasti's Phase 3 trial of CaPre, aimed at patients with high levels of triglycerides, isn't working out, explaining why the stock is down 69.11% to start 2020. One of the primary causes of concern with the Trilogy 1 Phase 3 trial of CaPre was that there were unanticipated levels of placebo response.

There’s No Miraculous Comeback Looming for Acasti Pharma Stock

Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1

Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre

Acasti Pharma lost $118 million in market capitalization on January 13. That makes Acasti Pharma stock a liability, not a bargain.

Sensible Investors Will Ditch Acasti Pharma for Amarin 

Acasti Pharma stock plunged after disappointing TRILOGY 1 trial results. TRILOGY 2 results in February mark the company's last chance.

Acasti Pharma Stock Has One Last Chance

Following unsuccessful Phase 3 clinical trial results for its core CaPre treatment, Acasti and ACST stock look doomed.
The post The Future Doesn’t Look Too Bright For Acasti Pharma Stock appeared first on InvestorPlace.

The Future Doesn’t Look Too Bright For Acasti Pharma Stock

Acasti hopes a second study of its CaPre drug, due for release next month, shows better results, but most investors have left ACST stock.
The post Acasti’s Losing Drug and ACST Stock Are Not for Weak Hearts appeared first on InvestorPlace.

Acasti’s Losing Drug and ACST Stock Are Not for Weak Hearts

Acasti got some bad news recently from the FDA regarding its main drug candidate.  And this news could make it tough for ACST stock to recover.

Does Acasti Stock Have a Future?

ACST stock was already a tough gamble due to the competition for omega-3-based drugs. However, without FDA approval, the underlying pharmaceutical is merely a gamble.

The Future of ACST Stock Is on Hold

Amarin Corporation Plc

AstraZeneca

Shares of Amarin Corp. PLC AMRN, +4.80% rose 4.8% in active afternoon trading Monday, after makers of drugs that rival Amarin's Vascepa, which is used to lower the risk of cardiovascular events in patients with high triglyceride levels reported disappointing trial results.

Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint

Shares of Acasti Pharma Inc (NASDAQ: ACST), which closed at $2.18 Friday, have entered penny stock territory after a negative data readout.

Acasti Shares Slump On Failed Late-Stage Trial, Amarin Moves In Sympathy

When Acasti posts Phase 3 trial results, ACST stock could re-visit recent highs. Here's why you should pay attention to the stock now.

Acasti Pharma Stock Could Soar Above $3 Soon

Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks

Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Micro-cap biopharma Acasti Pharma Inc (NASDAQ: ACST) issued an update regarding a delay in a clinical readout.

Acasti Delay's Data Readout For Drug To Treat Elevated Triglycerides

Expects to report Trilogy 1 topline results in January 2020   with topline results for Trilogy 2 still expected by the end of January 2020

Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Acasti Pharma (ACST) is having trouble on Monday as ACST stock has fallen a great deal, but what's behind the falling prices?
The post Acasti Pharma News: Why ACST Stock Is Plummeting 24% Today appeared first on InvestorPlace.

Acasti Pharma News: Why ACST Stock Is Plummeting 24% Today

On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020 On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

Acasti's Value Hidden In Plain Sight

Acasti Pharma - Winning The Heart Race

LAVAL, Québec, Nov.  18, 2019  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), released some preliminary new animal data today which provides additional insights into CaPre’s potential mechanism of action in diabetes. In the Company’s Phase 2 studies in humans, a statistically significant reduction of hemoglobin A1c (HbA1c) was seen in the 4 gram treatment arm of the COLT study. This is the same dose that is currently being tested in Acasti’s TRILOGY Phase 3 program in humans.  This positive HbA1c result In COLT was surprising at the time, and potentially unique to CaPre, as other therapeutic OM3s had previously shown no effect on glucose metabolism in a diabetic or pre-diabetic population. The main objective for this new mechanistic diabetes mouse study was to assess if CaPre acts on glucose and/or insulin in some unique manner, and to compare results head-to-head with icosapent ethyl (VASCEPA), a marketed omega-3 therapeutic, and metformin, a widely prescribed diabetic medication. Acasti collaborated with Professor André Marette, Ph.D. who conducted the study. Dr. Marette, who is the Director of the Pfizer Chair to study the pathogenesis of insulin resistance and cardiometabolic diseases at the University Laval, Quebec, conducted the study for Acasti in a widely used and well accepted animal model in diet-induced obese C57BL6 mice to compare the mechanisms of action of CaPre versus icosapent ethyl and metformin on insulin resistance and type 2 diabetes. A second, still ongoing study will also compare these same drugs in a fatty liver disease animal model. Dr. Marette is a highly regarded researcher of cardiometabolic disease, and he has published numerous papers in prestigious journals such as Nature Medicine.

Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q2 2020 Results - Earnings Call Transcript

Agreement provides Acasti long-term supply of raw krill oil through commercialization Agreement provides Acasti long-term supply of raw krill oil through commercialization

News for Acasti Pharma Stock (ACST)